Arcturus Therapeutics’ (ARCT) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, November 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average price target of $66.75.

Arcturus Therapeutics Trading Down 1.9 %

NASDAQ ARCT opened at $17.21 on Monday. The stock has a 50-day moving average of $18.91 and a 200-day moving average of $22.21. Arcturus Therapeutics has a 1-year low of $14.93 and a 1-year high of $45.00. The firm has a market cap of $466.17 million, a PE ratio of -7.75 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the previous year, the firm earned ($0.61) EPS. As a group, equities research analysts forecast that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.30% of the stock is currently owned by company insiders.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Arcturus Therapeutics during the 3rd quarter valued at $42,000. Quest Partners LLC boosted its holdings in Arcturus Therapeutics by 3,283.5% in the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 3,579 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Arcturus Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Arcturus Therapeutics during the second quarter worth about $142,000. Finally, Point72 DIFC Ltd acquired a new stake in Arcturus Therapeutics during the second quarter worth about $188,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.